



October 26, 2020

**Initiatives Against COVID-19 in Canada  
- Reached Agreements with Government of Canada to  
Receive Development Funding and Supply VLP Vaccine -**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President & Representative Director; Hiroaki Ueno) announced today that its affiliated company, Medicago Inc. (Head Office: Quebec, Canada; CEO; Bruce D. Clark) has reached agreements with the Government of Canada to receive 173 million CAD (approximately 13.7 billion Japanese Yen) funding for the development of plant-derived virus-like particle (VLP) vaccine (project code: MT-2766) for the prevention of coronavirus disease 2019 (COVID-19) and to supply up to 76 million doses of vaccine.

Medicago will use the funding received under an agreement to accelerate development of MT-2766 and will establish a vaccine manufacturing facility.

Medicago is conducting clinical studies of MT-2766 in Canada and phase 1 trial is nearing completion. Phase 2 trials will be started in November and phase 3 trials will begin in December to evaluate the safety and efficacy of the vaccine.

Mitsubishi Tanabe Pharma Group will work to develop and deliver MT-2766 to society as soon as possible, contributing even further to the prevention of COVID-19, a pressing social issue.

*Medicago release (October 23, 2020, local time)*

*Medicago signs agreements with the Government of Canada to supply up to 76 million doses of its recombinant plant-derived COVID-19 vaccine.*

<https://www.medicago.com/en/newsroom/medicago-signs-agreements-with-the-government-of-canada-to-supply-up-to-76-million-doses-of-its-recombinant-plant-derived-covid-19-vaccine/>

*Canadian Government of Canada Announcement (October 23, 2020, local time)*

*Prime Minister announces funding to advance the development of Canadian COVID-19 vaccine technologies*

<https://pm.gc.ca/en/news/news-releases/2020/10/23/prime-minister-announces-funding-advance-development-canadian-covid>

**Mitsubishi Tanabe Pharma Corporation**  
**Corporate Communications Department**

Media contacts: TEL:+81 6 6205 5119

**About VLP Vaccine**

A novel vaccine that employs virus-like particle (Virus Like Particle) manufacturing technology. VLP has the same external structure as viruses and are expected to have a high immune-acquisition effect (efficacy) when it adopted for vaccines. Since VLP does not have genetic information and viruses do not multiply in the body, VLP is expected to be a promising vaccine technology with excellent safety. Plant-based VLP manufacturing technology is also expected to enable large-scale production in a short period of time.